A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma
A Trial of Thymalfasin With Trans Arterial Chemo-Embolization (TACE) in the Treatment of Adult Patients With Unresectable Hepatocellular Carcinoma: A Phase II Trial
1 other identifier
interventional
N/A
1 country
5
Brief Summary
The objective of this Phase II trial is to compare the efficacy and safety of 6 months of treatment with thymalfasin plus trans arterial chemoembolization (TACE) with TACE alone in adult patients with non-surgical hepatocellular carcinoma (HCC).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 28, 2004
CompletedFirst Posted
Study publicly available on registry
April 30, 2004
CompletedJanuary 15, 2008
January 1, 2008
April 28, 2004
January 8, 2008
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- Signed written informed consent.
- Diagnosis of HCC by:
- Presence of HCC on biopsy (core biopsy), or, if biopsy is strongly contra-indicated due to safety or patient-related concerns, then the diagnosis of HCC can be determined by:
- A new hepatic defect on imaging with an AFP \> 1000 ng/ml, or
- A new hepatic defect on ultrasound or CT with an AFP \< 1000 ng/ml when one of the following is present:
- At least two additional imaging techniques show signs characteristic of HCC, or
- The new hepatic defect has doubled in diameter over time, or
- The AFP has progressively risen to \> 200 ng/ml and triples the mean baseline.
- HCC must be unresectable and non-transplantable.
- Hematocrit \> 30%, platelet count \>= 50,000 per microliter, WBC \> 2.0 x 109/L, and polymorphonuclear white cell count \>= 1.0 x 109/L.
- Adequate renal function as demonstrated by serum creatinine level \< 1.5 mg/dl.
- If the patient is a woman, she is using a definitive method of birth control in consultation with her physician, or is surgically sterile or post-menopausal.
You may not qualify if:
- Concomitant chronic use of any drug known to be hepatotoxic, or of any immunosuppressive drug (Use of oral contraceptives will not exclude an otherwise eligible patient).
- Presence of main portal vein thrombosis or hepatic artery malformation.
- HCC amenable to treatment by surgical resection or hepatic transplantation.
- HIV infection diagnosed by HIV seropositivity and confirmed by Western blot.
- Concomitant or prior history of malignancy other than HCC within the last 10 years, except for curatively treated skin cancer or surgically cured in situ carcinoma of the cervix.
- Active infectious process that is not of a self-limiting nature. TB and AIDS are examples of infectious processes that are not of a self-limiting nature.
- Pregnancy as documented by a urine pregnancy test. Women with reproductive potential must agree to practice an adequate method of birth control for the duration of the study.
- Alcohol or intravenous drug abuse within the previous 1 year.
- Previous treatment with thymalfasin.
- Patients with known hypersensitivity to iodine.
- Simultaneous participation in another investigational drug study, or participation in any clinical trial involving investigational drugs within 30 days of study entry.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (5)
California Pacific Medical Center
San Francisco, California, 94115, United States
University of Florida
Gainesville, Florida, 32610, United States
William Beaumont Hospital
Royal Oak, Michigan, 48073, United States
Columbia University
New York, New York, 10032, United States
Metropolitan Research
Fairfax, Virginia, 22031, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
April 28, 2004
First Posted
April 30, 2004
Last Updated
January 15, 2008
Record last verified: 2008-01